Konuma, T., Kondo, T., Kawata, T., Iwato, K., Sato, Y., Mori, T., Ohashi, K., Nakazawa, H., Sugahara, H., Ago, H., Eto, T., Imamura, Y., Fukuda, T., Kanda, Y., Atsuta, Y., Yano, S. and Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (2019) Hematopoietic Cell Transplantation for Acute Panmyelosis with Myelofibrosis: A Retrospective Study in Japan. Biology of Blood and Marrow Transplantation, 25, e23-e27.
https://doi.org/10.1016/j.bbmt.2018.08.006

has been cited by the following article:

• TITLE: Acute Panmyelosis with Myelofibrosis: A Rare Subtype of Acute Myeloid Leukemia

  AUTHORS: Alioune Badara Diallo, Sokhna Aissatou Touré, Moussa Seck, Mouhamed Keita, Elimane Seydi Bousso, Blaise Felix Faye, Saliou Diop

  KEYWORDS: Acute Panmyelosis with Myelofibrosis, Bone Marrow Fibrosis, Cytopenias

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.11 No.3, September 18, 2021

  ABSTRACT: Acute panmyelosis with myelofibrosis (APMF) is a subtype of acute myeloid leukemia (AML) classified among the category of “AML, not otherwise specified” in the WHO 2016 classification of hematopoietic tumors. It is a rare, fatal hematological neoplasm that is characterized by acute onset of cytopenias and bone marrow fibrosis in the absence of splenomegaly or fibrosis related morphological changes in the red blood cells. The difficulty of diagnosis and management explains why APMF is rarely reported in Africa. We report here the case of a 30-year-old man who presented with dizziness, palpitations and dyspnea. Diagnosis of APMF was retained on bone marrow histology and immunohistochemistry which showed bone marrow fibrosis and high cellularity with majority of myeloid blast cells. The patient was treated by low dose cytarabine monotherapy 30 mg/m2 per week. At 3 months of treatment, the patient was transfusion-independent, with normalization of hemoglobin and platelets counts. However, the death occurred after 8 months. This case highlights the diagnosis specificity and management of AMPF, knowing the number of potential differential diagnoses and difficulties of its therapeutic management.